v3.24.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance, beginning of period (in shares) at Dec. 31, 2022   68,847,382      
Balance, beginning of period at Dec. 31, 2022 $ 360,680 $ 7 $ 1,442,405 $ (3,601) $ (1,078,131)
Statement of Stockholders' Equity (Deficit)          
Vesting of restricted common stock awards (in shares)   146,209      
Vesting of restricted common stock awards 0        
Stock-based compensation expense 4,507   4,507    
Unrealized gain (loss) on marketable debt securities 1,322     1,322  
Net loss (49,036)       (49,036)
Balance, end of period (in shares) at Mar. 31, 2023   68,993,591      
Balance, end of period at Mar. 31, 2023 317,473 $ 7 1,446,912 (2,279) (1,127,167)
Balance, beginning of period (in shares) at Dec. 31, 2022   68,847,382      
Balance, beginning of period at Dec. 31, 2022 360,680 $ 7 1,442,405 (3,601) (1,078,131)
Statement of Stockholders' Equity (Deficit)          
Unrealized gain (loss) on marketable debt securities 2,149        
Net loss (134,345)        
Balance, end of period (in shares) at Sep. 30, 2023   81,668,796      
Balance, end of period at Sep. 30, 2023 360,462 $ 8 1,574,382 (1,452) (1,212,476)
Balance, beginning of period (in shares) at Mar. 31, 2023   68,993,591      
Balance, beginning of period at Mar. 31, 2023 317,473 $ 7 1,446,912 (2,279) (1,127,167)
Statement of Stockholders' Equity (Deficit)          
Exercise of stock options (in shares)   3,122      
Exercise of stock options 11   11    
Vesting of restricted common stock awards (in shares)   64,492      
Vesting of restricted common stock awards 0        
Stock-based compensation expense 5,215   5,215    
Issuance of common stock from public offering, net commissions, underwriting discounts and offering costs (in shares)   12,500,000      
Issuance of common stock from public offering, net commissions, underwriting discounts and offering costs 117,079 $ 1 117,078    
Issuance of common stock under employee stock purchase plan (in shares)   55,704      
Issuance of common stock under employee stock purchase plan 435   435    
Unrealized gain (loss) on marketable debt securities (6)     (6)  
Net loss (40,290)       (40,290)
Balance, end of period (in shares) at Jun. 30, 2023   81,616,909      
Balance, end of period at Jun. 30, 2023 399,917 $ 8 1,569,651 (2,285) (1,167,457)
Statement of Stockholders' Equity (Deficit)          
Vesting of restricted common stock awards (in shares)   51,887      
Vesting of restricted common stock awards 0        
Stock-based compensation expense 4,731   4,731    
Unrealized gain (loss) on marketable debt securities 833     833  
Net loss (45,019)       (45,019)
Balance, end of period (in shares) at Sep. 30, 2023   81,668,796      
Balance, end of period at Sep. 30, 2023 360,462 $ 8 1,574,382 (1,452) (1,212,476)
Balance, beginning of period (in shares) at Dec. 31, 2023   81,767,263      
Balance, beginning of period at Dec. 31, 2023 349,097 $ 8 1,580,241 198 (1,231,350)
Statement of Stockholders' Equity (Deficit)          
Exercise of stock options (in shares)   21,975      
Exercise of stock options 192   192    
Vesting of restricted common stock awards (in shares)   445,713      
Vesting of restricted common stock awards 0        
Stock-based compensation expense 7,585   7,585    
Unrealized gain (loss) on marketable debt securities (524)     (524)  
Net loss (61,950)       (61,950)
Balance, end of period (in shares) at Mar. 31, 2024   82,234,951      
Balance, end of period at Mar. 31, 2024 294,400 $ 8 1,588,018 (326) (1,293,300)
Balance, beginning of period (in shares) at Dec. 31, 2023   81,767,263      
Balance, beginning of period at Dec. 31, 2023 349,097 $ 8 1,580,241 198 (1,231,350)
Statement of Stockholders' Equity (Deficit)          
Unrealized gain (loss) on marketable debt securities 324        
Net loss (191,698)        
Balance, end of period (in shares) at Sep. 30, 2024   82,538,624      
Balance, end of period at Sep. 30, 2024 175,634 $ 8 1,598,152 522 (1,423,048)
Balance, beginning of period (in shares) at Mar. 31, 2024   82,234,951      
Balance, beginning of period at Mar. 31, 2024 294,400 $ 8 1,588,018 (326) (1,293,300)
Statement of Stockholders' Equity (Deficit)          
Vesting of restricted common stock awards (in shares)   121,643      
Vesting of restricted common stock awards 0        
Stock-based compensation expense 5,010   5,010    
Issuance of common stock under employee stock purchase plan (in shares)   72,920      
Issuance of common stock under employee stock purchase plan 322   322    
Unrealized gain (loss) on marketable debt securities (116)     (116)  
Net loss (67,607)       (67,607)
Balance, end of period (in shares) at Jun. 30, 2024   82,429,514      
Balance, end of period at Jun. 30, 2024 232,009 $ 8 1,593,350 (442) (1,360,907)
Statement of Stockholders' Equity (Deficit)          
Vesting of restricted common stock awards (in shares)   109,110      
Vesting of restricted common stock awards 0        
Stock-based compensation expense 4,802   4,802    
Unrealized gain (loss) on marketable debt securities 964     964  
Net loss (62,141)       (62,141)
Balance, end of period (in shares) at Sep. 30, 2024   82,538,624      
Balance, end of period at Sep. 30, 2024 $ 175,634 $ 8 $ 1,598,152 $ 522 $ (1,423,048)